{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:41:46Z","timestamp":1787164906151,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejso.2024.109499","type":"journal-article","created":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T21:16:02Z","timestamp":1732396562000},"page":"109499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Outcomes of intraperitoneal chemotherapy for the treatment of gastric cancer with peritoneal metastasis: A comprehensive systematic review and meta-analysis"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4549-3745","authenticated-orcid":false,"given":"Piers R.","family":"Boshier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Tekkis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8371-0010","authenticated-orcid":false,"given":"Alice","family":"Baggaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry D.","family":"Robb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Lafaurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Simkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George B.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Petty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10100","key":"10.1016\/j.ejso.2024.109499_bib1","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","article-title":"Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Collaborators","year":"2017","journal-title":"Lancet"},{"issue":"10100","key":"10.1016\/j.ejso.2024.109499_bib2","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Disease","year":"2017","journal-title":"Lancet"},{"issue":"1 Pt B","key":"10.1016\/j.ejso.2024.109499_bib3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.amjsurg.2022.01.024","article-title":"Patterns of gastric cancer metastasis in the United States","volume":"224","author":"Sirody","year":"2022","journal-title":"Am J Surg"},{"issue":"21","key":"10.1016\/j.ejso.2024.109499_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10214882","article-title":"The burden of peritoneal metastases from gastric cancer: a systematic review on the incidence, risk factors and survival","volume":"10","author":"Rijken","year":"2021","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.ejso.2024.109499_bib5","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ijc.28373","article-title":"Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors","volume":"134","author":"Thomassen","year":"2014","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2024.109499_bib6","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s10120-021-01160-1","article-title":"Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort","volume":"24","author":"Koemans","year":"2021","journal-title":"Gastric Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2024.109499_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-022-01828-7","article-title":"Intraperitoneal chemotherapy for unresectable peritoneal surface malignancies","volume":"83","author":"Guchelaar","year":"2023","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.ejso.2024.109499_bib8","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1007\/s11605-012-2059-3","article-title":"Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis","volume":"16","author":"Imano","year":"2012","journal-title":"J Gastrointest Surg"},{"issue":"10","key":"10.1016\/j.ejso.2024.109499_bib9","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.21873\/anticanres.12945","article-title":"Intraperitoneal and systemic chemotherapy for patients with gastric cancer with peritoneal metastasis: a phase II trial","volume":"38","author":"Shinkai","year":"2018","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.ejso.2024.109499_bib10","first-page":"1335","article-title":"Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination","volume":"30","author":"Fujiwara","year":"2010","journal-title":"Anticancer Res"},{"issue":"15","key":"10.1016\/j.ejso.2024.109499_bib11","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ejso.2024.109499_bib12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1515\/pp-2016-0011","article-title":"Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS)","volume":"1","author":"Solass","year":"2016","journal-title":"Pleura Peritoneum"},{"key":"10.1016\/j.ejso.2024.109499_bib13","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejso.2024.109499_bib14","unstructured":"Wells, G.A., et al. The Newcastle\u2013Ottawa scale (NOS) for assessing the quality of nonrandomised studies in Meta Analyses. [Acccessed June 2024] https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp?fbclid=IwAR3xy9Cb0mD2ec2WCQwn0MY7dvcXUFJRDK5YsG-YrxxNq8NqKJ8_j2EzmCc."},{"key":"10.1016\/j.ejso.2024.109499_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.ejso.2024.109499_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13063-022-06143-w","article-title":"SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation","volume":"23","author":"Bin","year":"2022","journal-title":"Trials"},{"issue":"13","key":"10.1016\/j.ejso.2024.109499_bib17","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1245\/s10434-022-11998-z","article-title":"Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases","volume":"29","author":"Chia","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2024.109499_bib18","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s10120-017-0710-0","article-title":"Phase I\/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis","volume":"20","author":"Cho","year":"2017","journal-title":"Gastric Cancer"},{"issue":"13","key":"10.1016\/j.ejso.2024.109499_bib19","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1245\/s10434-011-1770-8","article-title":"Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination","volume":"18","author":"Fujiwara","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2024.109499_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/jso.22057","article-title":"Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination","volume":"105","author":"Fujiwara","year":"2012","journal-title":"J Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2024.109499_bib21","first-page":"1305","article-title":"Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study","volume":"19","author":"Fushida","year":"2008","journal-title":"Oncol Rep"},{"issue":"5","key":"10.1016\/j.ejso.2024.109499_bib22","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00280-013-2122-0","article-title":"Phase I\/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis","volume":"71","author":"Fushida","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.ejso.2024.109499_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000084018","article-title":"Laparoscopic-assisted intraperitoneal chemotherapy for patients with scirrhous gastric cancer","volume":"51","author":"Ikeguchi","year":"2005","journal-title":"Chemotherapy"},{"issue":"9","key":"10.1016\/j.ejso.2024.109499_bib24","first-page":"4071","article-title":"A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis","volume":"32","author":"Imano","year":"2012","journal-title":"Anticancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.ejso.2024.109499_bib25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s10120-016-0684-3","article-title":"Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings","volume":"20","author":"Ishigami","year":"2017","journal-title":"Gastric Cancer"},{"issue":"19","key":"10.1016\/j.ejso.2024.109499_bib26","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2024.109499_bib27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4174\/astr.2021.100.4.209","article-title":"Treatment options for advanced gastric cancer with peritoneal metastasis: experience from a single institution in Korea","volume":"100","author":"Kim","year":"2021","journal-title":"Ann Surg Treat Res"},{"issue":"9","key":"10.1016\/j.ejso.2024.109499_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092334","article-title":"Can we reboot the role of intraperitoneal chemotherapy in the treatment for gastric cancer with peritoneal carcinomatosis?: a retrospective cohort study regarding minimally invasive surgery conjoined with intraperitoneal plus systemic chemotherapy","volume":"14","author":"Kim","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ejso.2024.109499_bib29","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1245\/s10434-023-14240-6","article-title":"Phase II study of intraperitoneal administration of paclitaxel combined with S-1 and cisplatin for gastric cancer with peritoneal metastasis","volume":"31","author":"Kobayashi","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2024.109499_bib30","first-page":"2223","article-title":"Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer","volume":"35","author":"Kurokawa","year":"2015","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ejso.2024.109499_bib31","first-page":"211","article-title":"Efficacy of conversion surgery after neoadjuvant intraperitoneal-systemic chemotherapy in treating peritoneal metastasis of gastric cancer","volume":"26","author":"Li","year":"2021","journal-title":"J BUON"},{"issue":"2","key":"10.1016\/j.ejso.2024.109499_bib32","doi-asserted-by":"crossref","DOI":"10.1515\/pp-2019-0035","article-title":"Bidirectional chemotherapy combining intraperitoneal docetaxel with intravenous 5-fluorouracil and oxaliplatin for patients with unresectable peritoneal metastasis from gastric cancer: the first study in Western countries","volume":"5","author":"Lo Dico","year":"2020","journal-title":"Pleura Peritoneum"},{"issue":"10","key":"10.1016\/j.ejso.2024.109499_bib33","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s10147-023-02384-0","article-title":"Clinical significance of intraperitoneal paclitaxel combined with systemic chemotherapy for gastric cancer with peritoneal metastasis","volume":"28","author":"Nakashima","year":"2023","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2024.109499_bib34","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1245\/s10434-020-09388-4","article-title":"Intraperitoneal administration of paclitaxel combined with S-1 plus oxaliplatin as induction therapy for patients with advanced gastric cancer with peritoneal metastases","volume":"28","author":"Saito","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2024.109499_bib35","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00423-021-02410-7","article-title":"Efficacy of conversion surgery after a single intraperitoneal administration of paclitaxel and systemic chemotherapy for gastric cancer with peritoneal metastasis","volume":"407","author":"Shinkai","year":"2022","journal-title":"Langenbeck's Arch Surg"},{"issue":"6","key":"10.1016\/j.ejso.2024.109499_bib36","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s10147-008-0836-5","article-title":"Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer","volume":"13","author":"Tamura","year":"2008","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2024.109499_bib37","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1002\/cam4.5277","article-title":"Study of SOX combined with intraperitoneal high-dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: a phase II single-arm clinical trial","volume":"12","author":"Tu","year":"2023","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.ejso.2024.109499_bib38","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/ajco.13659","article-title":"Phase 1 trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study)","volume":"18","author":"Vatandoust","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2024.109499_bib39","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10120-023-01452-8","article-title":"Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study","volume":"27","author":"Yang","year":"2024","journal-title":"Gastric Cancer"},{"issue":"6","key":"10.1016\/j.ejso.2024.109499_bib40","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ejso.2006.03.007","article-title":"Neoadjuvant treatment of gastric cancer with peritoneal dissemination","volume":"32","author":"Yonemura","year":"2006","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2024.109499_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010116","article-title":"Long term survival after cytoreductive surgery combined with perioperative chemotherapy in gastric cancer patients with peritoneal metastasis","volume":"12","author":"Yonemura","year":"2020","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.ejso.2024.109499_bib42","doi-asserted-by":"crossref","first-page":"956","DOI":"10.2174\/1389201019666181114121145","article-title":"Clinical efficacy of combination intravenous and intraperitoneal chemotherapy in the treatment of gastric cancer with peritoneal carcinomatosis","volume":"19","author":"Zhang","year":"2018","journal-title":"Curr Pharmaceut Biotechnol"},{"key":"10.1016\/j.ejso.2024.109499_bib43","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211036310","article-title":"Neoadjuvant intraperitoneal and systemic chemotherapy versus neoadjuvant systemic chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with peritoneal metastasis: a propensity Score matched analysis","volume":"20","author":"Zhang","year":"2021","journal-title":"Technol Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ejso.2024.109499_bib44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejso.2020.05.021","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer","volume":"47","author":"Alyami","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2024.109499_bib45","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1245\/s10434-023-13572-7","article-title":"Bidirectional approach with PIPAC and systemic chemotherapy for patients with synchronous gastric cancer peritoneal metastases (GCPM)","volume":"30","author":"Casella","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2024.109499_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.610572","article-title":"Systemic chemotherapy including ramucirumab in combination with pressurized intra-peritoneal aerosol chemotherapy is a safe treatment option for peritoneal metastasis of gastric cancer","volume":"10","author":"Feldbrugge","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2024.109499_bib47","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5230\/jgc.2018.18.e37","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in gastric cancer patients with peritoneal metastasis (PM): results of a single-center experience and register study","volume":"18","author":"Gockel","year":"2018","journal-title":"J Gastric Cancer"},{"issue":"6","key":"10.1016\/j.ejso.2024.109499_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061443","article-title":"Current medical care situation of patients in Germany undergoing pressurized intraperitoneal aerosol chemotherapy (PIPAC)","volume":"14","author":"Horvath","year":"2022","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.ejso.2024.109499_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16081559","article-title":"Pressurised intraperitoneal aerosolised chemotherapy-results from the first hundred consecutive procedures","volume":"16","author":"Hoskovec","year":"2024","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ejso.2024.109499_bib50","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1515\/pp-2016-0017","article-title":"Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2)","volume":"1","author":"Khomyakov","year":"2016","journal-title":"Pleura Peritoneum"},{"issue":"4","key":"10.1016\/j.ejso.2024.109499_bib51","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1515\/pp-2023-0038","article-title":"What is long-term survival in patients with peritoneal metastasis from gastric, pancreatic, or colorectal cancer? A study of patients treated with systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC)","volume":"8","author":"Kryh-Jensen","year":"2023","journal-title":"Pleura Peritoneum"},{"issue":"19","key":"10.1016\/j.ejso.2024.109499_bib52","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.3748\/wjg.v24.i19.2130","article-title":"Pressurized intraperitoneal aerosol chemotheprapy after misdiagnosed gastric cancer: case report and review of the literature","volume":"24","author":"Nowacki","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.ejso.2024.109499_bib53","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00423-023-03163-1","article-title":"Gastric cancer with peritoneal metastases: a single center outline and comparison of different surgical and intraperitoneal treatments","volume":"408","author":"Santullo","year":"2023","journal-title":"Langenbeck's Arch Surg"},{"issue":"1","key":"10.1016\/j.ejso.2024.109499_bib54","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1245\/s10434-021-10860-y","article-title":"Clinical outcome for patients managed with low-dose cisplatin and doxorubicin delivered as pressurized intraperitoneal aerosol chemotherapy for unresectable peritoneal metastases of gastric cancer","volume":"29","author":"Sindayigaya","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2024.109499_bib55","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919846402","article-title":"Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C\/D) in patients with gastric cancer and peritoneal metastasis: a phase II study","volume":"11","author":"Struller","year":"2019","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2024.109499_bib56","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s12029-021-00698-8","article-title":"Effect of pressurized intraperitoneal aerosol chemotherapy on the survival rate of patients with peritoneal carcinomatosis of gastric origin","volume":"53","author":"Tidadini","year":"2022","journal-title":"J Gastrointest Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2024.109499_bib57","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s12029-022-00843-x","article-title":"Oncological outcomes after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of peritoneal carcinomatosis","volume":"54","author":"Tidadini","year":"2023","journal-title":"J Gastrointest Cancer"},{"issue":"12","key":"10.1016\/j.ejso.2024.109499_bib58","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.ejso.2019.06.018","article-title":"Safety and preliminary efficacy of electrostatic precipitation during pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable carcinomatosis","volume":"45","author":"Willaert","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2024.109499_bib59","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1245\/s10434-020-08226-x","article-title":"Phase I trial of hyperthermic intraperitoneal chemoperfusion (HIPEC) with cisplatin, mitomycin, and paclitaxel in patients with gastric adenocarcinoma and associated carcinomatosis or positive cytology","volume":"27","author":"Blum Murphy","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2024.109499_bib60","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1245\/s10434-023-14379-2","article-title":"Cytoreduction and hyperthermic intraperitoneal paclitaxel and cisplatin for gastric cancer with peritoneal metastasis","volume":"31","author":"Buckarma","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2024.109499_bib61","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejso.2007.05.015","article-title":"Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer","volume":"34","author":"Facchiano","year":"2008","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2024.109499_bib62","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1245\/s10434-018-07140-7","article-title":"Laparoscopic hyperthermic intraperitoneal chemotherapy is safe for patients with peritoneal metastases from gastric cancer and may lead to gastrectomy","volume":"26","author":"Newhook","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2024.109499_bib63","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/jso.23889","article-title":"Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis","volume":"111","author":"Wu","year":"2015","journal-title":"J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2024.109499_bib64","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3892\/ol.2017.6342","article-title":"Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites","volume":"14","author":"Ni","year":"2017","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.ejso.2024.109499_bib65","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1186\/s12885-020-07601-x","article-title":"Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study","volume":"20","author":"Yu","year":"2020","journal-title":"BMC Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.ejso.2024.109499_bib66","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.21037\/jgo-20-121","article-title":"Surgery with hyperthermic intraperitoneal chemotherapy after response to induction chemotherapy in patients with peritoneal metastasis of gastric cancer","volume":"12","author":"Canbay","year":"2021","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2024.109499_bib67","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12957-018-1363-0","article-title":"Neoadjuvant intraperitoneal chemotherapy followed by radical surgery and HIPEC in patients with very advanced gastric cancer and peritoneal metastases: report of an initial experience in a western single center","volume":"16","author":"Fava","year":"2018","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ejso.2024.109499_bib68","article-title":"Conversion surgery for patients with advanced gastric cancer with peritoneal carcinomatosis","volume":"2021","author":"Lee","year":"2021","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.ejso.2024.109499_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133401","article-title":"Benefit of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and bidirectional chemotherapy for patients with gastric cancer with peritoneal carcinomatosis considering cytoreductive surgery","volume":"15","author":"Yu","year":"2023","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.ejso.2024.109499_bib70","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2217\/fon-2021-1414","article-title":"A phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis","volume":"18","author":"Lu","year":"2022","journal-title":"Future Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2024.109499_bib71","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znae116","article-title":"Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: a systematic review and meta-analysis","volume":"111","author":"Guchelaar","year":"2024","journal-title":"Br J Surg"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324015671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324015671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:50:04Z","timestamp":1740106204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798324015671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0748798324015671"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2024.109499","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of intraperitoneal chemotherapy for the treatment of gastric cancer with peritoneal metastasis: A comprehensive systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2024.109499","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109499"}}